Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Harvard Business School
McKinsey
Johnson and Johnson
Dow

Last Updated: January 23, 2022

Volunteer for clinical trials for VUMERITY at ClinicalTrialExchange

DrugPatentWatch Database Preview

VUMERITY Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Vumerity, and when can generic versions of Vumerity launch?

Vumerity is a drug marketed by Biogen Inc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in twenty-five countries.

The generic ingredient in VUMERITY is diroximel fumarate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the diroximel fumarate profile page.

DrugPatentWatch® Generic Entry Outlook for Vumerity

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 20, 2033. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for VUMERITY
Drug Prices for VUMERITY

See drug prices for VUMERITY

DrugPatentWatch® Estimated Generic Entry Opportunity Date for VUMERITY
Generic Entry Date for VUMERITY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE, DELAYED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VUMERITY

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
BiogenPhase 1
BiogenPhase 3
Banner Life Sciences LLCPhase 1

See all VUMERITY clinical trials

Paragraph IV (Patent) Challenges for VUMERITY
Tradename Dosage Ingredient NDA Submissiondate
VUMERITY CAPSULE, DELAYED RELEASE;ORAL diroximel fumarate 211855 2020-12-23

US Patents and Regulatory Information for VUMERITY

VUMERITY is protected by three US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VUMERITY is ⤷  Try it Free.

This potential generic entry date is based on patent ⤷  Try it Free.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VUMERITY

Prodrugs of fumarates and their use in treating various diseases
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: METHOD OF TREATING MULTIPLE SCLEROSIS

Prodrugs of fumarates and their use in treating various diseases
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free

Prodrugs of fumarates and their use in treating various diseases
Patent Number: ⤷  Try it Free
Patent Expiration: ⤷  Try it Free
Patented Use: METHOD OF TREATING MULTIPLE SCLEROSIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biogen Inc VUMERITY diroximel fumarate CAPSULE, DELAYED RELEASE;ORAL 211855-001 Oct 29, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Biogen Inc VUMERITY diroximel fumarate CAPSULE, DELAYED RELEASE;ORAL 211855-001 Oct 29, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Biogen Inc VUMERITY diroximel fumarate CAPSULE, DELAYED RELEASE;ORAL 211855-001 Oct 29, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Dow
Mallinckrodt
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.